MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aktis Oncology
AKTS
|
+$93.9M |
| 2 |
DBV Technologies
DBVT
|
+$88.1M |
| 3 |
Corcept Therapeutics
CORT
|
+$36.9M |
| 4 |
Travere Therapeutics
TVTX
|
+$33.9M |
| 5 |
Cytokinetics
CYTK
|
+$31.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$56.4M |
| 2 |
PTC Therapeutics
PTCT
|
+$32.7M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$17.4M |
| 4 |
Corvus Pharmaceuticals
CRVS
|
+$17.1M |
| 5 |
Ventyx Biosciences
VTYX
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q1 2026 Portfolio in Review
As of Q1 2026, MPM BioImpact held 49 positions worth $1.29B, up 48% from $874M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
MPM BioImpact deployed $290M of net new capital in Q1 2026, opening 11 new positions and adding to 20 existing holdings. Its largest new stake was Aktis Oncology: 4,835,872 shares worth $86.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Corvus Pharmaceuticals, an estimated $17.1M trimmed.
- MPM BioImpact's largest Q1 2026 buy was Aktis Oncology: 4,835,872 shares worth $86.5M.
- MPM BioImpact added most to DBV Technologies in Q1 2026, an estimated $88.1M increase.
- MPM BioImpact's biggest Q1 2026 reduction was Corvus Pharmaceuticals, cutting an estimated $17.1M.
- MPM BioImpact fully exited Madrigal Pharmaceuticals in Q1 2026, selling an estimated $56.4M.
- MPM BioImpact's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2026.
- MPM BioImpact opened 11 new positions and closed 8 in Q1 2026.
- MPM BioImpact's portfolio value rose 48% quarter-over-quarter to $1.29B.
Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.